Radioembolization has been demonstrated to allow locoregional therapy of patients with
hepatocellular carcinoma not eligible for transarterial chemoembolization or other local …

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) has limited treatment options;
long-term outcomes following intra-arterial radiation are unknown. We assessed clinical …

A multicenter analysis was conducted to evaluate the main prognostic factors driving
survival after radioembolization using yttrium‐90–labeled resin microspheres in patients …

PURPOSE: Intraarterial delivery of yttrium-90 (90Y)–bound microspheres (ie,
radioembolization) is a promising treatment for hepatocellular carcinoma (HCC). An early …

PURPOSE: To compare the effectiveness and toxicity of transcatheter arterial
chemoembolization (chemoembolization) and yttrium-90–labeled microspheres …

Abstract Radioembolization with yttrium-90 microspheres (90 Y-RE), either glass-or resin-
based, is increasingly applied in patients with unresectable liver malignancies. Clinical …

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and
affects millions worldwide. Due to the lack of effective systemic therapies for HCC …

BACKGROUND & AIMS: Chemoembolization is one of several standards of care treatment
for hepatocellular carcinoma (HCC). Radioembolization with Yttrium-90 microspheres is a …

Purpose To assess the safety and efficacy of yttrium-90 (90 Y) radioembolization when
performed in a superselective fashion for patients with unresectable hepatocellular …

Abstract Yttrium‐90 radioembolization (Y90RE) is a novel approach to radiation therapy for
hepatocellular carcinoma (HCC), never tested in phase 2 studies. Fifty‐two patients with …